These results could explain, at least partially, the observation by van der Veen et al. that p38MAPK inhibition had only a moderate beneficial effect on disease severity in the mouse model of anti-MPO IgG/LPS-induced glomerulonephritis [16]. This evidence concerns the gene MPO and glomerulonephritis.